Linagliptin for type 2 diabetes mellitus: a review of the pivotal clinical trials

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Therapeutic Advances in Endocrinology and Metabolism

• Publication date

  2012-08-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/2042018812449406PMID 23185685PMCID PMC3498850
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Linagliptin: A New DPP-4 Inhibitor for the Treatment of Type 2 Diabetes Mellitus

  2011cited by this paper
• Effect of linagliptin monotherapy on glycaemic control and markers of β‐cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial

  2011cited by this paper
• Standards of Medical Care in Diabetes—2011

  2011cited by this paper
• Use of Dipeptidyl Peptidase-4 Inhibitors and the Reporting of Infections: A Disproportionality Analysis in the World Health Organization VigiBase

  2011cited by this paper
• Safety and efficacy of linagliptin as add‐on therapy to metformin in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

  2011influential reference
• Assessment of the pharmacokinetic interaction between the novel DPP-4 inhibitor linagliptin and a sulfonylurea, glyburide, in healthy subjects.

  2011cited by this paper
• Linagliptin for the treatment of type 2 diabetes (pharmacokinetic evaluation)

  2011cited by this paper
• Efficacy and safety of linagliptin in persons with Type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24‐week randomized study 1

  2011influential reference
• Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double‐blind, placebo‐controlled study

  2011influential reference
• The Metabolism and Disposition of the Oral Dipeptidyl Peptidase-4 Inhibitor, Linagliptin, in Humans

  2010cited by this paper
• [Type-2 diabetes].

  2010cited by this paper
• Linagliptin (BI 1356), a potent and selective DPP‐4 inhibitor, is safe and efficacious in combination with metformin in patients with inadequately controlled Type 2 diabetes

  2010cited by this paper
• Evaluation of the pharmacokinetic interaction between the dipeptidyl peptidase-4 inhibitor linagliptin and pioglitazone in healthy volunteers.

  2010cited by this paper
• Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes.

  2010cited by this paper
• Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase‐4 inhibitor in male type 2 diabetes patients

  2009cited by this paper
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy

  2009influential reference
• Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement of the American Diabetes Association and the European Association for the Study of Diabetes

  2009cited by this paper
• Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes

  2008cited by this paper
• Defining and reporting hypoglycemia in diabetes: a report from the American Diabetes Association Workgroup on Hypoglycemia.

  2005cited by this paper
• The disease burden associated with overweight and obesity.

  1999cited by this paper

• Unveiling Pharmacological Promise of Mangifera indica (Haribhanga) Peel Extract: Exploring an Untapped Cultivar Through Biochemical and Computational Approaches

  2025cites this paper
• Ameliorative Effect of Empagliflozin and Linagliptin on Cisplatin-Induced Nephrotoxicity and Cardiotoxicity by Reducing Oxidative Stress

  2025cites this paper
• A Validated Ion‐Pair Reversed‐Phase High‐Performance Liquid Chromatography for Simultaneous Quantification of Metformin Hydrochloride, Empagliflozin, and Linagliptin in the Antidiabetic Drug Combination and Dissolution Media

  2025cites this paper
• Optimization of Linagliptin-Loaded Polymersomes via Response Surface Methodology: A Repurposed Therapeutic Strategy for Hepatic Encephalopathy Prevention

  2025cites this paper
• Elemental Imbalance in Disease Pathogenesis: The Promise of Chelating Peptides as Therapeutic Targets

  2025cites this paper
• Recent advances and structure-activity relationship studies of DPP-4 inhibitors as anti-diabetic agents.

  2024cites this paper
• Hemorrhagic bullous pemphigoid developing after linagliptin

  2024cites this paper
• DEVELOPMENT AND VALIDATION OF GREEN HPTLC METHOD FOR SIMULTANEOUS DETERMINATION OF DAPAGLIFLOZIN AND LINAGLIPTIN IN COMBINED DOSAGE FORM

  2024cites this paper
• Identification and Structural Characterization of Degradation Products of Linagliptin by Mass Spectrometry Techniques

  2024cites this paper
• Formulation Development and in-vitro Evaluation of Linagliptin Transdermal Patch Using Permeability Enhancer

  2023cites this paper
• Comparative Effectiveness of Glimepiride versus Linagliptin as add-on to Metformin in Type-2-Diabetes Mellitus

  2023cites this paper
• Importance of quinazoline and quinazolinone derivatives in medicinal chemistry

  2021cites this paper
• Therapeutic Advances in Diabetes, Autoimmune, and Neurological Diseases

  2021cites this paper
• Electrochemical Detection of Linagliptin and its Interaction with DNA

  2021cites this paper
• Therapeutic progression of quinazolines as targeted chemotherapeutic agents.

  2020cites this paper
• Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA)

  2020cites this paper
• Physiologically based pharmacokinetic model of the DPP-4 inhibitor linagliptin to describe its nonlinear pharmacokinetics in humans.

  2020cites this paper
• Current Treatment Trends in T2DM andImpact of COVID-19 among T2DM Patients: A Review

  2020cites this paper
• Linagliptin prevents left ventricular stiffening by reducing titin cleavage and hypophosphorylation

  2020cites this paper
• A Simple, Specific, Mass Compatible and Validated Gas Chromatographic Method for the Estimation of Piperidine-3-amine Content in Linagliptin Finished and Stability Samples without Derivatization

  2020cites this paper
• Solubility profile of linagliptin: designing of transdermal formulation

  2019cites this paper
• A new stability indicating reverse phase high performance liquid chromatography method for the determination of enantiomeric purity of a DPP‐4 inhibitor drug linagliptin

  2019cites this paper
• High dose of linagliptin induces thermogenic beige adipocytes in the subcutaneous white adipose tissue in diet-induced obese C57BL/6 mice

  2019cites this paper
• Effect of Linagliptin on Incretin-axis and Glycaemic Variability in T1DM.

  2018cites this paper
• Cost-Minimization Analysis of Linagliptin Compared to Sitagliptin in the Treatment of Type 2 Diabetes Mellitus from a Turkish Healthcare Perspective

  2017influential citation
• FORMULATION AND IN-VITRO EVALUATION OF NANOPARTICLES OF LINAGLIPTIN

  2017cites this paper
• Linagliptin versus sitagliptin in patients with type 2 diabetes mellitus: a network meta-analysis of randomized clinical trials

  2017cites this paper
• Hypoglycemia Incidence Rates and Associated Health Care Costs in Patients with Type 2 Diabetes Mellitus Treated with Second-Line Linagliptin or Sulfonylurea After Metformin Monotherapy

  2016cites this paper
• Combination of the dipeptidyl peptidase-4 inhibitor linagliptin with insulin-based regimens in type 2 diabetes and chronic kidney disease

  2015cites this paper
• Inhibidores de dipeptidil dipeptidasa-IV: de la teoría a la práctica

  2015cites this paper
• Islet vascularization in Type 2 Diabetes Mellitus

  2015cites this paper
• New pharmacological approaches to diabetes management

  2015cites this paper
• Dipeptidil dipeptidase-IV inhibidors: from the theory to the practice

  2015influential citation
• Clinical pharmacology of dipeptidyl peptidase 4 inhibitors indicated for the treatment of type 2 diabetes mellitus

  2015cites this paper
• Efficacy and safety of the dipeptidyl peptidase-4 inhibitor linagliptin in black/African American patients with type 2 diabetes: Pooled analysis from eight Phase III trials

  2015cites this paper
• Single-pill combination therapy for type 2 diabetes mellitus: linagliptin plus empagliflozin

  2015cites this paper
• Efficacy and safety of linagliptin in Hispanic/Latino patients with type 2 diabetes mellitus: a pooled analysis from six randomized placebo-controlled phase 3 trials

  2014influential citation
• Letter to the editor regarding: “Pharmacokinetics of teneligliptin in subjects with renal impairment.” Halabi et al., Clinical Pharmacology in Drug Development 2013;2:246–254

  2014cites this paper
• Efficacy and safety of linagliptin in subjects with long-standing type 2 diabetes mellitus (>10 years): evidence from pooled data of randomized, double-blind, placebo-controlled, phase III trials.

  2014cites this paper
• Linagliptin enhances neural stem cell proliferation after stroke in type 2 diabetic mice.

  2014cites this paper
• Bioequivalence of Linagliptin 5 mg Once Daily and 2.5 mg Twice Daily: Pharmacokinetics and Pharmacodynamics in an Open-label Crossover Trial

  2013cites this paper
• DPP-4 INHIBITOR LINAGLIPTIN: A NEW ANTI-DIABETIC DRUG IN THE TREATMENT OF TYPE-2 DIABETES

  2013cites this paper